

| Numéro de catalogue | HF813026 |
|---|---|
| Description |
Research Grade Fontolizumab (HF813026) is a humanized monoclonal antibody detecting Interferon gamma in ELISA, Bioactivity: FACS, Functional assay, Research in vivo. Suitable for Human.
Highlights
|
| Reactivité des espèces | Human |
| Applications | ELISA, Bioactivity: FACS, Functional assay, Research in vivo |
| Espèce hôte | Human |
| Clonalité | Monoclonal |
| Isotype | IgG1-nd |
| Système d'expression | Mammalian cells |
| Espèces | Human |
| Cible | Interferon gamma, IFN-gamma, Immune interferon, IFNG |
| Niveau d'endotoxines | < 10 EU/mg |
| Pureté | >95% as determined by SDS-PAGE. |
| Purification | Protein A/G purified from cell culture supernatant. |
| Numéro d'accès | P01579 |
| Forme | Liquid |
| Tampon de stockage | 0.01M PBS pH 7.4 Reférez-vous aux informations spécifiques sur le tampon dans la copie papier du datasheet ou dans le COA spécifique au lot. |
| Stabilité et stockage | Use a manual defrost freezer and avoid repeated freeze thaw cycles. Store at 2 to 8°C for frequent use. Store at -20 to -80°C for twelve months from the date of receipt. |
| Noms alternatifs | HuZAF, 326859-36-3 |
| Contexte | Interferon gamma (Interferon gamma,IFN-gamma,Immune interferon,IFNG) is a ~19 kDa protein. Type II interferon produced by immune cells such as T-cells and NK cells that plays crucial roles in antimicrobial, antiviral, and antitumor responses by activating effector immune cells and enhancing antigen presentation. Primarily signals through the JAK-STAT pathway after interaction with its receptor IFNGR1 to affect gene regulation. Upon IFNG binding, IFNGR1 intracellular domain opens out to allow association of downstream signaling components JAK2, JAK1 and STAT1, leading to STAT1 activation, nuclear translocation and transcription of IFNG-regulated genes. Many of the induced genes are transcription factors such as IRF1 that are able to further drive regulation of a next wave of transcription. Plays a role in class I antigen presentation pathway by inducing a replacement of catalytic proteasome subunits with immunoproteasome subunits. 1. El Bougrini, J. et al. (2006) Cellular and molecular biology (Noisy-le-Grand, France) 52, 9-15. PMID: 16914093 2. Hisamatsu, H. et al. (1996) The Journal of experimental medicine 183, 1807-16. PMID: 8666937 3. Greenlund, AC. et al. (1993) The Journal of biological chemistry 268, 18103-10. PMID: 8349687 4. Akiyama, K. et al. (1994) FEBS letters 343, 85-8. PMID: 8163024 5. Fabunmi, RP. et al. (2001) Journal of cell science 114, 29-36. PMID: 11112687 6. Lah, TT. et al. (1995) FEBS letters 363, 85-9. PMID: 7729559 |
| Note | For research use only. Not suitable for clinical or therapeutic use. |
| Isotype Control | Human IgG1 Recombinant Isotype Control Antibody (13R4) (HV080507) |

SDS-PAGE for Research Grade Fontolizumab




Contactez-nous pour les devis personnalisés, les demandes en gros et tout autre problème.
Courrier : [email protected]


+86-027-65523339
Bâtiment C, No. 666, Rue Shendunsi, Wuhan, 430206, Chine
中文
English
한국어
日本語
Español
Français
Русский